A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
2023-04-11
Target enrollment:
Participant gender:
Summary
This study includes two periods. In Period 1, Participants who meet eligibility criteria will
be randomized in a 1:1:1 ratio to receive a twice-daily oral LNK01001 Dose A or LNK01001 Dose
B or a matching placebo for 12 weeks. Participants who receive a placebo in Period 1 will be
re-randomized at Week 13 in a 1:1 ratio to receive a twice-daily oral LNK01001 Dose A or
LNK01001 Dose B for 12 weeks (period 2). Participants who receive LNK01001 ( Dose A and Dose
B) in Period 1 will maintain the treatment dose in Period 2.